STERIS plc STE
- Market cap
- $20.4B
- P/E
- 25.4×
Follow STE
STERIS plc (STE) EV/Sales
As of 25 September 2026, STERIS plc (STE) trades at a EV/Sales of 3.6×. Over the past ten years it has ranged from 2.2× (August 2015) to 7.2× (December 2021); the current reading is higher than 29% of that period. That is above the Medical Devices industry median of 2.4× and in line with the Healthcare sector median of 3.6×.
EV/Sales, daily
Annual
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 3.9× | (11.87%) |
| FY2025 | 4.4× | (8.22%) |
| FY2024 | 4.8× | (0.08%) |
| FY2023 | 4.8× | (22.39%) |
| FY2022 | 6.2× | 9.53% |
| FY2021 | 5.7× | 35.61% |
| FY2020 | 4.2× | (0.57%) |
| FY2019 | 4.2× | 24.87% |
| FY2018 | 3.4× | 23.79% |
| FY2017 | 2.7× | (3.64%) |
Quarterly
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.6× | (6.95%) |
| Mar 2026 | 3.9× | (14.00%) |
| Dec 2025 | 4.5× | (0.49%) |
| Sep 2025 | 4.6× | 0.26% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 1.4× |
| PHG Koninklijke Philips N.V. compare | 1.4× |
| GEHC GE HealthCare Technologies Inc. compare | 1.9× |
| ZBH Zimmer Biomet Holdings, Inc. compare | 2.9× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.6× |
| STE STERIS plc | 3.6× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.8× |
| DXCM DexCom, Inc. compare | 6.5× |
| PEN Penumbra, Inc. compare | 7.9× |
| Medical Devices industry median | 2.4× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on STE
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement